Exelixis Inc. Stock
Price
Target price
€21.44
€21.44
0.510%
0.11
0.510%
€26.01
17.04.24 / Tradegate
WKN: 936718 / Symbol: EXEL / Name: Exelixis / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Exelixis Inc. Stock
Exelixis Inc. gained 0.510% compared to yesterday.
Exelixis Inc. is currently one of the favorites of our community with 15 Buy predictions and no Sell predictions.
As a result the target price of 26 € shows a positive potential of 21.27% compared to the current price of 21.44 € for Exelixis Inc..
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | 0.510% | -2.722% | 2.193% | 18.683% | -2.011% | 8.888% | 9.836% |
| Ironwood Pharmaceuticals | -0.670% | -1.342% | -6.962% | -28.641% | -29.327% | -17.416% | -36.856% |
| Novocure Ltd | -0.620% | -16.992% | -12.179% | -80.821% | -20.946% | -92.975% | - |
| Iovance Biotherapeutics Inc. | -0.720% | -5.387% | -13.284% | 108.380% | 41.714% | -56.039% | - |
Comments
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Royal Bank of Canada from $26.00 to $28.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Barclays PLC from $24.00 to $25.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at William Blair.
Show more
Ratings data for EXEL provided by MarketBeat
News
2 Stocks Under $30 to Buy and Hold
What is a reasonable sum of money to start investing in stocks? $10,000? $1,000? $500? The truth is, thanks to online brokers who now offer trades at low or no fees and fractional shares, investors
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q4 2023 Earnings CallFeb 06, 2024, 5:00 p.m. ET
Operator
Source Fool.com
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q3 2023 Earnings CallNov 01, 2023, 5:00 p.m. ET
Operator
Source Fool.com